DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for X-linked endothelial corneal dystrophy — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleX-linked endothelial corneal dystrophy maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for x-linked endothelial corneal dystrophy is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
diphosphoinositol pentakisphosphate kinase 2 (PPIP5K2) — PPIP5K2 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet atpdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 3T54 · 1.9 Å · ligand ADENOSINE-5'-TRIPHOSPHATE (ATP). Experimental structure, not a prediction.
What the evidence adds up to
In Fuchs Endothelial Corneal Dystrophy (FECD), a progressive disease affecting the corneal endothelium in both eyes, the only therapeutic choice has historically been corneal transplantation using donor corneas. A 2017 study evaluated phacoemulsification with central circular descemetorhexis in patients with FECD. In 63.8% of patients, visual rehabilitation was achieved without endothelial transplantation. A 2018 study examined a method combining descemetorhexis with accelerated collagen crosslinking. In primary endothelial dystrophy, corneal state improvement and restoration of transparency were observed in 66.6% of cases, attributed to migration of endothelial cells from the periphery to the central zone. In secondary endothelial dystrophy, the same treatment method was ineffective, and the reasons for failure were not clear.
A 2021 article describes Descemet stripping only (DSO) as a viable treatment option for certain cases of FECD, noting that successful DSO provides information about the pathophysiology of the disease. A 2018 perspective article reviews current knowledge of the genetics and pathophysiology of FECD and introduces potent therapeutic modalities that show promise as new treatments, but does not report specific clinical results for any drug or intervention beyond corneal transplantation.
No drug therapy is mentioned in any of these abstracts. The reported interventions are surgical removal of Descemet's membrane and endothelium, with or without collagen crosslinking. The sample sizes are small: the 2017 study reports on patients with mean central corneal pachymetry of 587.8±44.8 µm, but does not give the total number. The 2018 study reports 66.6% efficacy in primary dystrophy but does not give the number of patients. What is still missing is a drug treatment that targets the underlying pathophysiology, randomised controlled trials comparing surgical techniques to no intervention or to transplantation, and patient stratification to identify who will benefit from descemetorhexis alone versus who will need donor tissue.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Cornea · 2021 · 21 citations
Descemet Stripping Only for Fuchs Endothelial Corneal Dystrophy: Will It Become the Gold Standard?
AbstractABSTRACT: Descemet stripping only (DSO) has become a viable treatment option for certain cases of Fuchs Endothelial Corneal Dystrophy (FECD). This article describes the history of the development of DSO, its current status, and what successful DSO tells us about the pathophysiology of FECD. Remaining questions and future directions are also highlighted.
The Open Ophthalmology Journal · 2018 · 16 citations · open access
Perspective of Future Potent Therapies for Fuchs Endothelial Corneal Dystrophy
AbstractBACKGROUND: Fuchs Endothelial Corneal Dystrophy (FECD) is a progressive disease that affects the corneal endothelium in both eyes. Recent studies have identified a novel genetic basis for FECD, and basic research findings have provided evidence for its underlying pathophysiology. Since its first description by Ernst Fuchs in 1910, the only therapeutic choice has been corneal transplantation using donor corneas. However, accumulating evidence suggests that a change in this "rule" may be imminent. CONCLUSIONS: This article reviews the current knowledge of the genetics and pathophysiology of FECD, and it introduces some potent therapeutic modalities that show promise as new treatments for this disorder.
Russian Annals of Ophthalmology · 2017 · 12 citations
Clinical and functional results of one-step phaco surgery and central descemetorhexis for cataract and Fuchs primary endothelial corneal dystrophy
AbstractPoor visual function associated with Fuchs endothelial corneal dystrophy (FECD) is one of the main indications for keratoplasty. Reports of successful visual rehabilitation of patients with spontaneous or scheduled removal of the Descemet's membrane and the endothelium or donor material adhesion failure, suggest this research direction perspective. AIM: to evaluate the potential as well as clinical and functional outcomes of phacoemulsification with central circular descemetorhexis in patients with Fuchs endothelial corneal dystrophy. MATERIAL AND METHODS: , and central corneal pachymetry - 587.8±44.8 µm. After phacoemulsification with IOL implantation, a 4 mm tap was created from the epithelial side of the cornea. Central circular descemetorhexis was done using a microhook. The membrane was removed with microforceps. RESULTS: . CONCLUSION: In 63.8% of patients, visual rehabilitation was achieved without endothelial transplantation, which provides new prospects for tissue-saving technologies in patients with endothelial corneal dystrophy.
Ophthalmology Reports · 2018 · 1 citations · open access
Comparative assessment of the efficacy of primary and secondary corneal endothelial dystrophy treatment by isolated descemetorhexis and accelerated collagen crosslinking method
AbstractThe article examines the efficacy of the authors method of endothelial corneal dystrophy treatment, inclu ding descemetorhexis and accelerated collagen crosslinking. In primary endothelial dystrophy, corneal state improvement and restoration of its transparency were observed in 66.6% of cases (due to migration of endothelial cells from the periphery to the сentral zone). In secondary endothelial dystrophy, the treatment method described in the present article is ineffective, and the reasons for failures are not quite clear and require further investigation.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
